Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 40.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 289,279 shares of the company’s stock after purchasing an additional 83,117 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $4,701,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in TEVA. Raymond James & Associates grew its stake in Teva Pharmaceutical Industries by 5.1% in the 2nd quarter. Raymond James & Associates now owns 815,944 shares of the company’s stock valued at $13,259,000 after acquiring an additional 39,610 shares during the last quarter. Blue Trust Inc. grew its stake in Teva Pharmaceutical Industries by 164.0% in the 2nd quarter. Blue Trust Inc. now owns 10,434 shares of the company’s stock valued at $170,000 after acquiring an additional 6,481 shares during the last quarter. Coronation Fund Managers Ltd. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $1,334,000. Baader Bank Aktiengesellschaft grew its stake in Teva Pharmaceutical Industries by 57.7% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 210,098 shares of the company’s stock valued at $3,413,000 after acquiring an additional 76,909 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $188,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the sale, the insider now owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $0.01 during trading hours on Monday, hitting $18.25. 4,914,866 shares of the stock were exchanged, compared to its average volume of 10,320,007. The stock has a 50-day simple moving average of $16.91 and a 200-day simple moving average of $15.16. Teva Pharmaceutical Industries Limited has a 12 month low of $8.06 and a 12 month high of $18.58. The stock has a market cap of $20.67 billion, a price-to-earnings ratio of -44.54, a price-to-earnings-growth ratio of 1.57 and a beta of 0.90. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. Jefferies Financial Group raised their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Finally, Piper Sandler restated an “overweight” rating and issued a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.